Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Transcenta Holding Limited ( (HK:6628) ) just unveiled an announcement.
Transcenta Holding Limited has entered into a strategic collaboration and non-exclusive licensing agreement with Taiwan-listed EirGenix Inc., under which EirGenix will adopt Transcenta’s HiCB continuous biomanufacturing platform for its biologics development programs and manufacturing operations, including services for CDMO clients seeking intensified and continuous production solutions. The deal provides Transcenta with upfront, milestone and future royalty payments, supporting reinvestment in its technology platform and R&D pipeline, while broadening the global deployment of its cost-efficient manufacturing technology and reinforcing its positioning as a leader in continuous bioprocessing aimed at improving affordability and access to innovative biologic therapies worldwide.
The most recent analyst rating on (HK:6628) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Transcenta Holding Limited stock, see the HK:6628 Stock Forecast page.
More about Transcenta Holding Limited
Transcenta Holding Limited is a Cayman Islands-registered biopharmaceutical company focused on developing and manufacturing biologic therapies. The company has built a proprietary Highly Intensified Continuous Bioprocessing (HiCB) platform aimed at improving production efficiency, product consistency and lowering manufacturing costs to expand global access to high-quality, affordable biologics.
Average Trading Volume: 1,332,013
Technical Sentiment Signal: Sell
Current Market Cap: HK$959.7M
For an in-depth examination of 6628 stock, go to TipRanks’ Overview page.